Figure 3

PAR2 blockade reduces C-PAF-induced lung inflammation and production of chemokines in BALB/c mice. (A) Mice were pretreated with ENMD1068 (0.5 mg/kg, i.p.). One hour later the mice were stimulated with C-PAF (10^–7 M; i.n.). After 24 h, the lungs were collected and stained with H&E (20 × scale of 100 μM; 40 × scale of 50 μM). Panel a-b: PBS group, which exhibits normal histological features and no evidence of lung inflammation; Panel c-d: C-PAF group showing perivascular and peribronchiolar inflammation; Panel e–g: ENMD1068 pretreated group, shows cellular infiltration reduced as assessed by the histopathology score. (B–E) mice were pretreated with ENMD1068 (0.5 mg/kg, i.p.) 1 h prior to administration of C-PAF (10^–7 M; i.n.). NAG and MPO levels were evaluated 24 h later and CXCL1 and CXCL2 levels were assessed 1, 4, and 12 h later. The results are representative of three independent experiments and expressed as mean ± SEM from six mice per group. Statistical analysis was assessed by ANOVA followed by Newman-Keuls test, Panel g: ***p < 0.001 compared to C-PAF group and ^#p < 0.001 compared to control group (PBS); (B–E) ***p < 0.001, **p < 0.01 and *p < 0.05 compared to C-PAF group and ^#p < 0.001, ^##p < 0.01 and ^###p < 0.05 compared to control group (PBS).